Kardatuxan (Rivaroxaban)

Rivaroxaban works by selectively inhibiting factor Xa, a key enzyme in the coagulation cascade. By blocking factor Xa, it prevents the conversion of prothrombin to thrombin, thereby reducing fibrin clot formation and providing anticoagulation without directly affecting platelet function.

The appropriate dose of Kardatuxan is determined by a qualified prescriber based on the specific indication, patient characteristics, renal function, and other clinical factors. Patients should follow the dosing instructions provided by their healthcare professional.

Safety data for rivaroxaban in pregnancy and lactation are limited. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To order Kardatuxan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kardatuxan (rivaroxaban) belongs to the direct oral anticoagulant (DOAC) class, offering fixed dosing without routine laboratory monitoring, unlike warfarin which requires INR checks. Compared with other DOACs, rivaroxaban has a once‑daily regimen for many indications, but drug‑specific interaction profiles and renal dosing considerations differ.

Kardatuxan tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Kardatuxan is taken orally, usually with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a full glass of water and not chewed or crushed unless specifically instructed.

The most serious risks include major bleeding events such as intracranial hemorrhage, gastrointestinal bleeding, and spinal or epidural hematoma. Patients should seek immediate medical attention for signs of severe bleeding, sudden severe headache, vision changes, or unexplained bruising.

Kardatuxan is contraindicated in patients with active pathological bleeding, severe hepatic impairment, or those who are pregnant unless the benefit outweighs the risk. It should also be avoided in individuals with known hypersensitivity to rivaroxaban or any of its excipients.